Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of GST101 in RAS-mutant advanced solid tumors
CTR20263708Phase 2Active
- Sponsor
- Genuine Seed Therapeutics
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GST101 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer (PC), sponsored by Genuine Seed Therapeutics. Started Oct 2026; status: active.
02
Drugs
GST101
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20263708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263708.